The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular correlates of PD-L1 expression in patients with non-small cell lung cancer.
 
Hira Rizvi
No Relationships to Disclose
 
Chaitanya Bandlamudi
No Relationships to Disclose
 
Adam Jacob Schoenfeld
No Relationships to Disclose
 
Jennifer L. Sauter
Stock and Other Ownership Interests - Merck; Thermo Fisher Scientific
 
Kathryn Cecilia Arbour
Consulting or Advisory Role - AstraZeneca
 
Amanda Beras
No Relationships to Disclose
 
Jacklynn V. Egger
No Relationships to Disclose
 
Marc Ladanyi
Honoraria - Merck (I)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck (I); NCCN/AstraZeneca; Takeda
Research Funding - Helsinn Therapeutics; Loxo (Inst)
 
Mark Donoghue
No Relationships to Disclose
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Ascentage Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Daiichi Sankyo; Elucida Oncology; Genentech/Roche; Harpoon Therapeutics; Ipsen; Loxo; PharmaMar; PharmaMar; Seagen
Research Funding - Abbvie/Stemcentrx (Inst); Daiichi Sankyo (Inst); Merck (Inst); Viralytics (Inst)
 
Barry S. Taylor
No Relationships to Disclose
 
Matthew David Hellmann
Stock and Other Ownership Interests - Shattuck Labs
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Janssen; Merck; Mirati Therapeutics; Nektar; Novartis; Shattuck Labs; Syndax
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb